BioSapien Extends Pre-Series A Round to $8M, Adds Globivest and Global Talent to Power Next Phase of Growth 

Healthtech innovator BioSapien has announced an extension of its pre-Series A funding round to over $8 million, adding MENA-based Globivest to its investor roster. The UAE and US-based startup, known for its breakthrough 3D-printed drug delivery platform MediChip™, is now backed by a formidable investor lineup including Global Ventures, Golden Gate Ventures, and Dara Holdings.

The capital injection will accelerate product development and global expansion, with a sharp focus on regulatory readiness, clinical validation, and commercial deployment. To drive this next stage, BioSapien has appointed 12 new executives across R&D, regulatory affairs, medical leadership, and operations.

Among the senior hires:

• Joseph Borrello, PhD joins as Chief Technology Officer

• Dr. Sonia Ramamoorthy, MD, MBA, FACS, as Head of Medical Affairs

• Agnes Westelinck, PharmD, as Head of Regulatory – U.S.

• Dr. Dirk Richter, MD, FACS, as Head of Regulatory – UAE

Additional hires span manufacturing, quality control, compliance, and clinical development, reflecting BioSapien’s intent to build a globally aligned team of technical excellence.

Founded in 2018 by Dr. Khatija Ali, BioSapien’s flagship technology MediChip™ is a 3D-printed, slow-release drug delivery system attachable to tissue, offering targeted therapeutic delivery with minimal systemic side effects — a paradigm shift for oncology and beyond. “Two of the greatest challenges for young, fast-growing companies are establishing a strong balance sheet and attracting high-quality talent,” said Dr. Khatija Ali, Founder & CEO of BioSapien. “With this raise and the calibre of our new hires, BioSapien is now positioned to lead the charge in transforming localised cancer treatment into a globally scalable solution.”

A Strategic Fit for Impact-Driven Investment

Globivest, the MENA region’s first women-led, gender lens venture capital fund, joins the round as both an investor and strategic partner. The fund’s focus on health, social, and environmental change makes BioSapien a natural fit, especially as the startup’s MediChip™ platform aligns with the WHO’s One Health agenda. “We back companies that don’t just promise innovation – they deliver transformative, science-backed solutions with the power to shift paradigms,” said Dr. Laura-Joy Boulos, Partner at Globivest. “MediChip™ is scalable, precise, and deeply aligned with our One Health mission. We’re proud to support Dr. Ali and her team as they build the future of accessible precision medicine.”

What’s Next

With new capital, talent, and global investor backing, BioSapien is gearing up for:

• Expanded clinical programs and regulatory submissions in the US and UAE

• Strategic partnerships across pharma and biotech

• Increased production capabilities for its 3D-printed delivery systems

• International hiring to support its global roadmap

As the demand for localised, less toxic cancer therapies continues to rise, BioSapien is positioning itself at the frontier of precision drug delivery — offering a science-backed, patient-first alternative to conventional systemic treatment approaches.